Ocean Biomedical, Inc. announced that the company and Polar Multi-Strategy Master Fund, a significant long-time financing partner of Ocean Biomedical, agreed to amend the agreement between the parties related to the Forward Shares Purchase Agreement entered into in February 2023.
Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the company and Polar Multi-Strategy Master Fund (Polar), a significant long-time financing partner of Ocean Biomedical, agreed to amend the agreement between the parties related to the Forward Shares Purchase Agreement entered into in February 2023. Polar and its affiliates have a history of supporting Ocean Biomedical, both preceding the company’s de-SPAC transaction in February 2023 and also in connection with the closing of that transaction.
This new amendment to the Forward Shares Purchase Agreement is intended as an extension of that support as the amendment provides Ocean Biomedical additional flexibility to, from time to time, potentially access capital under the in-place Forward Shares Purchase Agreement as market conditions fluctuate, and, lowering the “Seller VWAP Trigger Event” serves to narrow the circumstances under which Polar could elect to terminate the agreement prior to its prescribed termination date. The Seller VWAP Trigger Event does not prescribe when, or at what price, Polar can elect to sell shares under the agreement. Ocean Biomedical did not pay Polar any new fee or provide any other new consideration for the accommodations made by Polar, nor did the amendment result in a dilutive offering.
“Ocean Biomedical is pleased to have Polar as a long term investor and partner that is excited about the company’s potential to deliver lifesaving treatments in the areas of oncology, fibrosis and infectious disease. Ocean Biomedical believes that today’s announcement regarding the forward purchase agreement further illustrates Polar’s commitment to Ocean Biomedical’s success by providing the company the flexibility it needs to access capital and further its clinical mission.” - Chirinjeev Kathuria, Executive Chairman and co-founder.
About Ocean Biomedical
Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems for the people who need it most.
To learn more, visit www.oceanbiomedical.com.
Forward-Looking Statements
The information included herein and in any oral statements made on behalf of Ocean Biomedical, Inc. (the “Company”) or otherwise in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations; the expected timing and success of investigational new drug (“IND”) filings for our initial product candidates; statements regarding the expected timing of our IND-enabling studies; the frequency and timing of filing additional INDs; expectations regarding the availability and addition of future assets to our pipeline; the advantages of any of our pipeline assets and platforms; the potential benefits of our product candidates; potential commercial opportunities; the timing of key milestones for our programs; the future financial condition, results of operations, business strategy and plans, and objectives of management for future strategy and operations; and statements about industry trends and other companies in the industry. These forward-looking statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management, and they are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
Any discoveries announced by the Company are based solely on laboratory and animal studies. The Company has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that any treatment tested by the Company will prove safe or effective in humans, and that any clinical benefits of any such treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.
Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and in the Company’s subsequent Quarterly Reports on Form 10-Q and other documents filed by the Company from time to time with the SEC and which are and are available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. We do not undertake any obligation to update any forward-looking statements made by us. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Ocean Biomedical Investor Relations
connect@oceanbiomedical.com
Kevin Kertscher
Communications Director
